dc.contributor.author
Pruß, Axel
dc.contributor.author
Chandrasekar, Akila
dc.contributor.author
Sánchez-Ibáñez, Jacinto
dc.contributor.author
Lucas-Samuel, Sophie
dc.contributor.author
Kalus, Ulrich
dc.contributor.author
Rabenau, Holger F.
dc.date.accessioned
2022-08-12T12:06:21Z
dc.date.available
2022-08-12T12:06:21Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/35879
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-35594
dc.description.abstract
Background: Although transmission of pathogenic viruses through human tissue grafts is rare, it is still one of the most serious dreaded risks of transplantation. Therefore, in addition to the detailed medical and social history, a comprehensive serologic and molecular screening of the tissue donors for relevant viral markers for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) is necessary. In the case of reactive results in particular, clear decisions regarding follow-up testing and the criteria for tissue release must be made.
Methods: Based on the clinical relevance of the specific virus markers, the sensitivity of the serological and molecular biological methods used and the application of inactivation methods, algorithms for tissue release are suggested.
Results: Compliance with the preanalytical requirements and assessment of a possible hemodilution are mandatory requirements before testing the blood samples. While HIV testing follows defined algorithms, the procedures for HBV and HCV diagnostics are under discussion. Screening and decisions for HBV are often not as simple, e.g., due to cases of occult HBV infection, false-positive anti-HBc results, or early window period positive HBV NAT results. In the case of HCV diagnostics, modern therapies with direct-acting antivirals, which are often associated with successful treatment of the infection, should be included in the decision.
Conclusion: In HBV and HCV testing, a high-sensitivity virus genome test should play a central role in diagnostics, especially in the case of equivocal serology, and it should be the basis for the decision to release the tissue. The proposed test algorithms and decisions are also based on current European recommendations and standards for safety and quality assurance in tissue and cell banking.
en
dc.subject
Donor screening
en
dc.subject
Tissue donation
en
dc.subject
Virus inactivation
en
dc.subject
Virus safety
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1159/000513179
dcterms.bibliographicCitation.journaltitle
Transfusion Medicine and Hemotherapy
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Karger
dcterms.bibliographicCitation.pagestart
12
dcterms.bibliographicCitation.pageend
21
dcterms.bibliographicCitation.volume
48
dcterms.rightsHolder.note
Copyright applies in this work.
dcterms.rightsHolder.url
http://rightsstatements.org/vocab/InC/1.0/
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.note.author
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
de
refubium.note.author
This publication is shared with permission of the rights owner and made freely accessible through a DFG (German Research Foundation) funded license at either an alliance or national level.
en
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33708048
dcterms.isPartOf.issn
1660-3796
dcterms.isPartOf.eissn
1660-3818